978 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
CELG Celgene Corporation $95.61 $71.92B Downtrend
Article Searches
Stocks To Watch: Investors Recharge After Soothing Fedspeak https://seekingalpha.com/article/4150390-stocks-watch-investors-recharge-soothing-fedspeak?source=feed_tag_editors_picks Feb 24, 2018 - Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday
Better Buy: Biogen Inc. vs. Celgene Corporation https://www.fool.com/investing/2018/02/23/better-buy-biogen-inc-vs-celgene-corporation.aspx?source=iedfolrf0000001 Feb 23, 2018 - Which big biotech stock wins in a head-to-head matchup?
Sorrento Therapeutics: Will This Novel CAR-T Deliver Robust Value? https://seekingalpha.com/article/4149882-sorrento-therapeutics-will-novel-car-t-deliver-robust-value?source=feed_sector_healthcare Feb 23, 2018 - Sorrento has a diverse pipeline of developing therapeutics.Next-generation CAR-T based on CD38 has substantial value.Strong management from the leadership of Dr. Henry Ji to push for robust growth.
IRA Portfolio 1 Year Buying-Selling Update And Now 5.8% Dividend Yield https://seekingalpha.com/article/4149645-ira-portfolio-1-year-buying-selling-update-now-5_8-percent-dividend-yield?source=feed_all_articles Feb 22, 2018 - Good News: Dividend income will be up 28.6% in 2018 with the new portfolio construction.Bad News: Portfolio value only up 9% excluding dividends, and 14.1% with them.Final dividend yield was 5.1% on o
Merck to Buy Australian Firm to Boost Immunotherapy Pipeline http://www.zacks.com/stock/news/293253/merck-to-buy-australian-firm-to-boost-immunotherapy-pipeline?cid=CS-ZC-FT-293253 Feb 22, 2018 - Merck (MRK) to buy Australian oncolytic immunotherapies maker Viralytics Limited to strengthen its presence in the fast growing immuno-oncology market.
Your Daily Pharma Scoop: Buy Heron At Dips, Aimmune Positive Data, Voyager And AbbVie Ink Deal https://seekingalpha.com/article/4148670-daily-pharma-scoop-buy-heron-dips-aimmune-positive-data-voyager-abbvie-ink-deal?source=feed_sector_healthcare Feb 21, 2018 - Heron is worth buying at dips.Aimmune’s lead product candidate succeeds in late-stage study.Voyager and AbbVie sign exclusive agreement.
Biotechs: Still Well Placed For More Gains https://seekingalpha.com/article/4148492-biotechs-still-well-placed-gains?source=feed_all_articles Feb 20, 2018 - Sharp market correction triggered by interest rate concerns creates opportunities.Market transitions into a more typical rally and pullback mode, with a continued firm uptrend.Biotech stocks are exper
Celgene's Otezla reduces oral ulcers in late-stage study in rare autoimmune disorder https://seekingalpha.com/news/3332168-celgenes-otezla-reduces-oral-ulcers-late-stage-study-rare-autoimmune-disorder?source=feed_news_all Feb 20, 2018 - Results from a Phase 3 clinical trial evaluating Celgene's (NASDAQ:CELG) OTEZLA (apremilast) in patients with active Behçet’s Disease with oral ulcers demonstrated a treatment effect. The
What's in Store for Juno Therapeutics (JUNO) in Q4 Earnings? http://www.zacks.com/stock/news/293017/whats-in-store-for-juno-therapeutics-juno-in-q4-earnings?cid=CS-ZC-FT-293017 Feb 20, 2018 - Although Juno Therapeutics' (JUNO) product portfolio lacks revenue figures, the company's most advanced pipeline candidates, JCAR017 and JCAR014, might still drive the stock in Q4.
David Rolfe Axes TreeHouse Foods, Exxon Mobil in 4th Quarter http://www.gurufocus.com/news/643343/david-rolfe-axes-treehouse-foods-exxon-mobil-in-4th-quarter Feb 19, 2018 - David Rolfe Axes TreeHouse Foods, Exxon Mobil in 4th Quarter, Stocks: THS,XOM,CELG,T,PYPL,BRK.B,AAPL,GOOGL,V,FAST, David Rolfe, release date:Feb 19, 2018

Pages: 123456...98

Page 1>

Related Companies

Name Exchange Price Mkt Cap
AZN Astrazeneca PLC NYSE $34.01 $86.14B
LLY Eli Lilly and Company NYSE $78.75 $86.28B
AGN Allergan plc. NYSE $162.09 $53.54B
GSK GlaxoSmithKline PLC NYSE $36.84 $91.33B
SNY Sanofi NYSE $40.13 $100.25B
Sector: Health Care > Industry: Major Pharmaceuticals
DeepLinks for Celgene
CELG - Google Finance https://www.google.com/finance?q=CELG Industry related info and international coverage Summary News
CELG - Bloomberg http://www.bloomberg.com/research/stocks/snapshot/snapshot.asp?ticker=CELG Original news and commentary from Bloomberg Charts Financials with pensions Snapshot Earnings Transactions People Options